QIAGEN Rides On Solid QuantiFERON-TB Sales Amid Several Woes
Zacks Investment Research | Nov 17, 2019 10:24PM ET
On Nov 15, we issued an updated research report on QIAGEN N.V. (NYSE:QGEN) . The company's business is consistently getting a boost from its flourishing molecular diagnostic market. However, overdependence on relationships with collaborative partners and foreign exchange headwinds are downsides. The stock currently has a Zacks Rank #3 (Hold).
QIAGEN ended the third quarter on a mixed note with earnings beating and revenues missing the estimates. The company registered revenue growth across majority of its geographies and operating segments. We are also upbeat about the company’s Sample to Insight portfolio progress in the period.
Developments like QuantiFERON-TB’s growth at 18% CER and continued momentum of the QIAstat-Dx and QIAsymphony are appreciative. The recently-inked 15-year strategic partnership with Illumina (NASDAQ:ILMN) is also encouraging. Additionally, we are impressed with the company’s strong international performance. Further, it steadily gained traction from its collaboration with DiaSorin.
QIAGEN N.V. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.